MedTrace Logo

Intracavitary Injection of hUMSCs in Acute Basal Ganglia Hematoma After Stereotactic Aspiration

NCT04074408 · Status: UNKNOWN · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 100

Last updated 2020-05-26

No results posted yet for this study

Summary

A study to examine the safety and potential effectiveness of human umbilical cord mesenchymal stem cells (hUMSCs) in adults who have suffered spontaneous cerebral hemorrhage in basal ganglia. The hypothesis is that hUMSCs will be safe and can improve neurological function after intracerebral hemorrhage so that improve the prognosis of patients.

Conditions

  • Basal Ganglia Hematoma

Interventions

PROCEDURE

stereotactic surgery

stereotactic aspiration surgery

BIOLOGICAL

hUMSCs

single intracavitary infusion 1 day after stereotactic aspiration surgery

BIOLOGICAL

placebo

single intracavitary infusion 1 day after stereotactic aspiration surgery

Sponsors & Collaborators

  • The First Affiliated Hospital, University of Science and Technology of China

    collaborator OTHER

  • Zhejiang University

    collaborator OTHER

  • First Affiliated Hospital of Fujian Medical University

    collaborator OTHER

  • Jinhua Hospital, School of Medicine, Zhejiang University

    collaborator UNKNOWN

  • Taizhou Hospital

    collaborator OTHER

  • Second Affiliated Hospital, School of Medicine, Zhejiang University

    lead OTHER

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
30 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-05-31
Primary Completion
2022-11-30
Completion
2023-11-30

Countries

  • China

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04074408 on ClinicalTrials.gov